Aileron Therapeutics’ Shareholders Approve Major Stock Proposals
Company Announcements

Aileron Therapeutics’ Shareholders Approve Major Stock Proposals

The latest update is out from Aileron Therapeutics Inc (ALRN).

At the 2023 Annual Meeting, shareholders of the company decisively passed several key proposals, notably the increase of authorized common stock from 45 million to 100 million shares and the approval of the conversion of Series X Non-Voting Convertible Preferred Stock into common stock. Additionally, stockholders elected three Class III directors, expanded the 2021 Stock Incentive Plan by 3 million shares, endorsed executive compensation plans, and chose to hold future compensation votes annually. The appointment of Marcum LLP as the independent auditor was also ratified. Post-meeting, the company anticipates a conversion of preferred stock, which will significantly increase the number of common shares, subject to ownership limitations.

See more insights into ALRN stock on TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistIs ALRN a Buy, Before Earnings?
TheFlyAileron Therapeutics’ ALRN-6924 to be acquired by Advancium Health Network
TheFlyAileron completes enrollment of Cohort 2 of Phase 1b trial of LTI-03
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App